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Letters to the Editorapplicable when considering thoracic
endovascular aortic repair (TEVAR)
for dissections.2 DeBakey type III dis-
sections are divided into 2 groups:
type IIIa, in which the dissection is con-
fined to the supradiaphragmatic de-
scending aorta, and type IIIb, in which
it extends beyond the diaphragm. Defi-
nition is important from the point of
achieving false lumen–free treatment
or only aneurysm exclusion with TE-
VAR. According to our modest experi-
ence, we3 obtained ‘‘cure’’ with
TEVAR in patients with type IIIa dis-
sections by coverage of the proximal
tear and complete reattachment of the
intima and media levels.2
Endovascular treatment is per-
formed to exclude the aneurysm in
type IIIb dissections.2,4 However, pa-
tency of the false lumen is a major
prognostic factor in the mid to long
run in patients with type IIIb aortic dis-
sections both after open repair5 and af-
ter TEVAR.2,4 After TEVAR, the
proximal false lumen does not always
thrombose and blood flow may con-
tinue outside the stent graft.2 This
may increase the size of the aneurysm,
lead to a new aneurysm formation at
the excluded segment of the aorta, or
even lead to collapse of the stent graft
system.2 The postoperative course
marked by such a complication in 1
of our patients (Figure E1), who was
further treated with TEVAR.
Even if the proximal false lumen
completely thromboses, it is still under
the stress of systemic blood pressure.
In contrast to the theory that thick
thrombus protects from rupture, intra-
aortic thrombus diminishes aortic
wall nourishment, and ruptures fre-
quently occur in the presence of aortic
thrombus.
In brief, TEVAR fails to completely
compress the false lumen in chronic
type IIIb dissections either because of
high pressure inside the false lumen
or because it is intended not to, since
some visceral arteries may originate
from this lumen. The issue is different
during surgery or perioperative hybrid
therapy. Surgical treatment mediatesThe Journalreplacement of the dilated segment of
aorta. Distal anastomosis may provide
perfusion of only the true lumen or
both lumina.5 And TEVAR during
surgical treatment differs from con-
ventional deployment, in which stent
grafts are delivered and expanded
into a pressureless aorta, a technique
that has better success rates on fol-
low-up.4
Once again, we congratulate the au-
thors for their very valuable contribu-
tion. We believe surgical treatment
still seems the valid option for the
treatment of chronic type B dissections
with low complication rates in experi-
enced centers in the current era.5
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ISCHEMICCARDIOMYOPATHY:
IS THE CLEVELAND
CLINIC MODELVALID?
To the Editor:
Clinically significant variables are
required before any statistical model
can provide useful decision making
during surgical management of ische-
mic cardiomyopathy. Models would
otherwise be created with an insuffi-
cient database, so that statistically val-
idated results might yield valueless
clinical conclusions that might worsen
the development of congestive heart
failure (CHF) symptoms and fatal ven-
tricular arrhythmias after their applica-
tion to the enormous population with
CHF.
The recent Cleveland Clinic
Foundation (CCF) report1 concludes
that coronary artery bypass grafting
(CABG) alone or in combination
with surgical ventricular restoration
(SVR) provides similar long-term re-
sults to the recent National Institutes
of Health Surgical Treatment of Ische-
mic Heart Failure (STICH) trial that
evaluated quality-of-life outcome,
rehospitalization rate, andmortality af-
ter surgical management of ischemic
cardiomyopathy.2 Their findings es-
tablish CABG therapy alone as a suffi-
cient treatment, fulfill current
angioplasty revascularization goals,
diminish cardiologic interest in SVR,
and limit expansion of the surgeon’s
interest in learning a new procedure
for CHF management.
The innovative statistical model hy-
pothesis of no outcome difference be-
tween CABG versus CABG with
SVR becomes invalid if the ischemic
cardiomyopathy clinical database
does not show increased left ventricu-
lar end-systolic volume index
(LVESVI) rather than reduced systolic
ejection fraction3 as the indicator of
heart failure. The original STICH trial
entry criteria required a preoperative
LVESVI of greater than 60 mL/m2,
as measured by means of cardiac mag-
netic resonance imaging or single pho-
ton emission computed tomographyy c Volume 140, Number 5 1203
Letters to the Editor(SPECT), and excluded echocardio-
graphic analysis because of volume
underestimation from ventricular
asynergy.4 The extensive CCF report
tables do not include this vital compo-
nent. The STICH trial report excluded
volume measurement in 66% of pa-
tients having CABG and SVR, and
an almost similar exclusion rate oc-
curred in patients having CABG alone.
Moreover, the accepted trial design de-
fined a 30% LVESVI reduction as
a satisfactory SVR procedure.5 An in-
adequate SVR procedure was done in
the STICH trial because volume
reduction was only 19%.5 The CCF
authorship should provide preopera-
tive and postoperative LVESVI mea-
surements so that readers can
determine whether the right patients
were selected and whether a proper
SVR volume reduction was done.
The STICH trial required that an
area of myocardial necrosis of greater
than 35% be present to qualify for ran-
domization to CABG or CABG plus
SVR. Temporary akinesia, dyskinesia,
or both can result from stunning or hi-
bernation of nonscarred muscle. The
STICH trial did not report myocardial
necrosis. The only entry criterion for
SVR was dysfunction caused by aki-
nesia or dyskinesia without necrosis
documentation and included 13% of
patients without previous myocardial
infarction. Furthermore, the CCF re-
ports that only 153 patients had necro-
sis determined by means of
gadolinium cardiac magnetic reso-
nance imaging because the 111 dobut-
amine echocardiographs cannot be
used quantify the area of necrosis.
How can the authors be sure the
6-cm left ventricular end-diastolic di-
ameter was due to scar rather than
stunning?
The role of experience is another ba-
rometer of the STICH trial’s validity
that was recently questioned.5 This in-
quiry is related to the learning curve
because the STICH trial recruited 96
centers to perform an innovative pro-
cedure in 490 patients. The CCF is
a single institution and thereby par-1204 The Journal of Thoracic andtially addresses this question. There
is historic precedent for the role of ex-
perience at CCF because Sheldon and
colleagues’ 1976 report6 established
the vital importance of CABG therapy
by demonstrating excellent graft pa-
tency and 1% mortality in 1000 con-
secutive patients. Most importantly,
this classic study contradicted the Na-
tional Institutes of Health Veterans
Hospital CABG report showing that
inexperienced centers recorded
a higher graft occlusion rate and mor-
tality.7 Unfortunately, the current
CCF report does not follow the strat-
egy of Sheldon and colleagues6 be-
cause long-term mortality is reported
without evaluating the quality of the
SVR procedure in sufficiently reduc-
ing left ventricular volume. Moreover,
LVESVI measurements in the CCF
database would allow readers to com-
pare their findings with the approxi-
mately 40% LVESVI reduction
(30%–58% range) achieved by 1500
patients reported from 12 international
centers,5 the database for which dem-
onstrated improved late outcomes in
patients having CABG plus SVR com-
pared with late mortality outcomes
from patients having CABG alone.8,9
The effect of a satisfactory volume
reduction rate after SVR was con-
firmed by the 2001 Di Donato and
associates’ report10 of the Dor experi-
ence, whereby higher late mortality
occurred when postoperative LVESVI
was greater than 60 mL/m2. Di Donato
and coworkers’ recent 2010 registry
report11 from Milan demonstrates sig-
nificantly higher late SVR mortality
rates if postoperative volume reduc-
tion of 40% attained an LVESVI of
greater than 60 mL/m2 versus less
than 60 mL/m2. Consequently, the
question is not ‘‘Have you done
SVR?’’ but rather ‘‘Did you do an ad-
equate SVR procedure?’’
This CCF analysis indirectly ad-
dresses the role of ventricular volume
by showing that CABG and mitral
valve procedures (MVP) have inferior
late mortality results when compared
with CABG, CABG and SVR, andCardiovascular Surgery c November 20heart transplantation. Markedly in-
creased LVESVI from mitral insuffi-
ciency is the most likely cause, even
though LVESVI was not described.
The surgical approach of addressing
the ‘‘vessel valve and ventricle’’8,12
applies to patients undergoing simulta-
neous CABG, MVP, and SVR, but the
article does not indicate analysis of
these patients. In contrast, the Recon-
structive Endoventricular Surgery, Re-
turning Torsion, Original Radius, and
Elliptical Shape to the LV (RE-
STORE) analysis shows that their 5-
year mortality was similar to that of pa-
tients undergoing CABG with SVR
and SVR alone.8 The surgical theme
of reducing ventricular volume by
means of SVR thereby applies to pa-
tients with MVP in ischemic cardio-
myopathy, yet this decision option
that also solves mitral insufficiency
volume expansion is not considered.
The CCF statistical analysis contri-
butions are superb gifts to our spe-
cialty because they have improved
our decision-making process. How-
ever, the hallmark of a validated
prediction model in decision making
for ischemic cardiomyopathy must be-
come linked to the established clinical
variables of importance, namely
LVESVI, necrosis, and adequate vol-
ume reduction rate. These important
variables were not included in the
CCF study. Their model might poten-
tially mislead the surgical and cardiol-
ogy community.
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